Bioartificial livers in vitro and in vivo: tailoring biocomponents to the expanding variety of applications

Bibliography

• Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet 2010;376:190-201
   PubMed Web of Science ®Google Scholar
• Nibourg GA, Hoekstra R, van der Hoeven TV, et al. Increased hepatic functionality of the human hepatoma cell line HepaRG cultured in the AMC bioreactor. Int J Biochem Cell Biol 2013;45:1860-8
   PubMed Web of Science ®Google Scholar
• Selden C, Spearman CW, Kahn D, et al. Evaluation of encapsulated liver cell spheroids in a fluidised-bed bioartificial liver for treatment of ischaemic acute liver failure in pigs in a translational setting. PLoS One 2013;8:e82312
   PubMedGoogle Scholar
• NCT01471028. 2011. Available from: www.clinicaltrials.gov
   Google Scholar
• Godoy P, Hewitt NJ, Albrecht U, et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 2013;87:1315-530
   PubMed Web of Science ®Google Scholar
• Giobbe GG, Tonon F, Zambon A, et al. Optimization of human pluripotent stem cell differentiation into hepatic cells under a stable microfluidic oxygen gradient. J Hepatol 2014;60:S102
   Google Scholar
• Lee SA, No da Y, Kang E, et al. Spheroid-based three-dimensional liver-on-a-chip to investigate hepatocyte-hepatic stellate cell interactions and flow effects. Lab Chip 2013;13:3529-37
   PubMed Web of Science ®Google Scholar
• Van de Stolpe A, den Toonder J. Workshop meeting report Organs-on-Chips: human disease models. Lab Chip 2013;13:3449-70
   PubMed Web of Science ®Google Scholar
• Andria B, Bracco A, Cirino G, Chamuleau R. Liver cell culture devices. Cell Medicine 2010;1:55-70
   Google Scholar
• Nibourg GA, Chamuleau RA, van Gulik TM, Hoekstra R. Proliferative human cell sources applied as biocomponent in bioartificial livers: a review. Expert Opin Biol Ther 2012;12:905-21
   PubMed Web of Science ®Google Scholar
• Park JK, Lee DH. Bioartificial liver systems: current status and future perspective. J Biosci Bioeng 2005;99:311-19
   PubMed Web of Science ®Google Scholar
• Hanid MA, Davies M, Mellon PJ, et al. Clinical monitoring of intracranial pressure in fulminant hepatic failure. Gut 1980;21:866-9
   PubMed Web of Science ®Google Scholar
• Bernal W, Hyyrylainen A, Gera A, et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. J Hepatol 2013;59:74-80
   PubMed Web of Science ®Google Scholar
• Riordan SM, Williams R. Perspectives on liver failure: past and future. Semin Liver Dis 2008;28:137-41
   PubMed Web of Science ®Google Scholar
• Sekiyama KD, Yoshiba M, Thomson AW. Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin Exp Immunol 1994;98:71-7
   PubMed Web of Science ®Google Scholar
• Rolando N, Wade J, Davalos M, et al. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000;32:734-9
   PubMed Web of Science ®Google Scholar
• Azoulay D, Samuel D, Ichai P, et al. Auxiliary partial orthotopic versus standard orthotopic whole liver transplantation for acute liver failure: a reappraisal from a single center by a case-control study. Ann Surg 2001;234:723-31
   PubMed Web of Science ®Google Scholar
• Chenard-Neu MP, Boudjema K, Bernuau J, et al. Auxiliary liver transplantation: regeneration of the native liver and outcome in 30 patients with fulminant hepatic failure – a multicenter European study. Hepatology 1996;23:1119-27
   PubMed Web of Science ®Google Scholar
• Tsiaoussis J, Newsome PN, Nelson LJ, et al. Which hepatocyte will it be? Hepatocyte choice for bioartificial liver support systems. Liver Transpl 2001;7:2-10
   PubMed Web of Science ®Google Scholar
• Eguchi S, Lilja H, Hewitt WR, et al. Loss and recovery of liver regeneration in rats with fulminant hepatic failure. J Surg Res 1997;72:112-22
   PubMed Web of Science ®Google Scholar
• Flendrig LM, la Soe JW, Jorning GG, et al. In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound nonwoven polyester matrix for hepatocyte culture as small aggregates. J Hepatol 1997;26:1379-92
   PubMed Web of Science ®Google Scholar
• Erro E, Bundy J, Massie I, et al. Bioengineering the liver: scale-up and cool chain delivery of the liver cell biomass for clinical targeting in a bioartificial liver support system. Biores Open Access 2013;2:1-11
   Google Scholar
• Hsu WM, Carraro A, Kulig KM, et al. Liver-assist device with a microfluidics-based vascular bed in an animal model. Ann Surg 2010;252:351-7
   PubMedGoogle Scholar
• Hughes B. Industry concern over EU hepatotoxicity guidance. Nat Rev Drug Discov 2008;7:719
   PubMed Web of Science ®Google Scholar
• Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009;16:3041-53
   PubMed Web of Science ®Google Scholar
• Galinski MR, Meyer EV, Barnwell JW. Plasmodium vivax: modern strategies to study a persistent parasite’s life cycle. Adv Parasitol 2013;81:1-26
   Google Scholar
• Gondeau C, Pichard-Garcia L, Maurel P. Cellular models for the screening and development of anti-hepatitis C virus agents. Pharmacol Ther 2009;124:1-22
   PubMed Web of Science ®Google Scholar
• Tanner M, de Savigny D. Malaria eradication back on the table. Bull World Health Organ 2008;86:82
   PubMed Web of Science ®Google Scholar
• Dembele L, Franetich JF, Lorthiois A, et al. Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures. Nat Med 2014;20:307-12
   PubMed Web of Science ®Google Scholar
• Meuleman P, Leroux-Roels G. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. Antiviral Res 2008;80:231-8
   PubMed Web of Science ®Google Scholar
• Allen JW, Khetani SR, Bhatia SN. In vitro zonation and toxicity in a hepatocyte bioreactor. Toxicol Sci 2005;84:110-19
   PubMed Web of Science ®Google Scholar
• Domansky K, Inman W, Serdy J, et al. Perfused multiwell plate for 3D liver tissue engineering. Lab Chip 2010;10:51-8
   PubMed Web of Science ®Google Scholar
• Takayama K, Kawabata K, Nagamoto Y, et al. 3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing. Biomaterials 2013;34:1781-9
   PubMed Web of Science ®Google Scholar
• Nyberg SL, Hardin J, Amiot B, et al. Rapid, large-scale formation of porcine hepatocyte spheroids in a novel spheroid reservoir bioartificial liver. Liver Transpl 2005;11:901-10
   PubMed Web of Science ®Google Scholar
• Shen C, Zhang G, Qiu H, Meng Q. Acetaminophen-induced hepatotoxicity of gel entrapped rat hepatocytes in hollow fibers. Chem Biol Interact 2006;162:53-61
   PubMed Web of Science ®Google Scholar
• Carpentier B, Gautier A, Legallais C. Artificial and bioartificial liver devices: present and future. Gut 2009;58:1690-702
   Google Scholar
• Carraro A, Hsu WM, Kulig KM, et al. In vitro analysis of a hepatic device with intrinsic microvascular-based channels. Biomed Microdevices 2008;10:795-805
   Google Scholar
• Novik E, Maguire TJ, Chao P, et al. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem Pharmacol 2010;79:1036-44
   PubMed Web of Science ®Google Scholar
• Jozefczuk J, Prigione A, Chavez L, Adjaye J. Comparative analysis of human embryonic stem cell and induced pluripotent stem cell-derived hepatocyte-like cells reveals current drawbacks and possible strategies for improved differentiation. Stem Cells Dev 2011;20:1259-75
   PubMed Web of Science ®Google Scholar
• Beigel J, Fella K, Kramer PJ, et al. Genomics and proteomics analysis of cultured primary rat hepatocytes. Toxicol In Vitro 2008;22:171-81
   PubMed Web of Science ®Google Scholar
• Baker TK, Carfagna MA, Gao H, et al. Temporal gene expression analysis of monolayer cultured rat hepatocytes. Chem Res Toxicol 2001;14:1218-31
   PubMed Web of Science ®Google Scholar
• Azuma H, Paulk N, Ranade A, et al. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 2007;25:903-10
   PubMed Web of Science ®Google Scholar
• Burkard A, Dahn C, Heinz S, et al. Generation of proliferating human hepatocytes using Upcyte(R) technology: characterisation and applications in induction and cytotoxicity assays. Xenobiotica 2012;42:939-56
   PubMed Web of Science ®Google Scholar
• Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol 1976;13:29-83
   PubMedGoogle Scholar
• OprodFraczek J, Bolleyn J, Vanhaecke T, et al. Primary hepatocyte cultures for pharmaco-toxicological studies: at the busy crossroad of various anti-dedifferentiation strategies. Arch Toxicol 2013;87:577-610
   PubMed Web of Science ®Google Scholar
• Huang SM, Temple R, Throckmorton DC, Lesko LJ. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 2007;81:298-304
   PubMed Web of Science ®Google Scholar
• Guguen-Guillouzo C, Guillouzo A. General review on in vitro hepatocyte models and their applications. Methods Mol Biol 2010;640:1-40
   PubMedGoogle Scholar
• Chamuleau RA, Deurholt T, Hoekstra R. Which are the right cells to be used in a bioartificial liver? Metab Brain Dis 2005;20:327-35
   PubMed Web of Science ®Google Scholar
• Yu LJ, Matias J, Scudiero DA, et al. P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos 2001;29:304-12
   PubMed Web of Science ®Google Scholar
• Nyberg SL, Remmel RP, Mann HJ, et al. Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver. Ann Surg 1994;220:59-67
   PubMed Web of Science ®Google Scholar
• Mavri-Damelin D, Damelin LH, Eaton S, et al. Cells for bioartificial liver devices: the human hepatoma-derived cell line C3A produces urea but does not detoxify ammonia. Biotechnol Bioeng 2008;99:644-51
   PubMed Web of Science ®Google Scholar
• Kia R, Sison RL, Heslop J, et al. Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet? Br J Clin Pharmacol 2013;75:885-96
   PubMed Web of Science ®Google Scholar
• Banas A, Teratani T, Yamamoto Y, et al. Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology 2007;46:219-28
   PubMed Web of Science ®Google Scholar
• Kazemnejad S, Allameh A, Soleimani M, et al. Biochemical and molecular characterization of hepatocyte-like cells derived from human bone marrow mesenchymal stem cells on a novel three-dimensional biocompatible nanofibrous scaffold. J Gastroenterol Hepatol 2009;24:278-87
   PubMed Web of Science ®Google Scholar
• Fausto N. Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology 2004;39:1477-87
   PubMed Web of Science ®Google Scholar
• Duret C, Gerbal-Chaloin S, Ramos J, et al. Isolation, characterization, and differentiation to hepatocyte-like cells of nonparenchymal epithelial cells from adult human liver. Stem Cells 2007;25:1779-90
   PubMed Web of Science ®Google Scholar
• Fonsato V, Herrera MB, Buttiglieri S, et al. Use of a rotary bioartificial liver in the differentiation of human liver stem cells. Tissue Eng Part C Methods 2010;16:123-32
   PubMed Web of Science ®Google Scholar
• Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-72
   PubMed Web of Science ®Google Scholar
• McKernan R, Watt FM. What is the point of large-scale collections of human induced pluripotent stem cells? Nat Biotechnol 2013;31:875-7
   PubMed Web of Science ®Google Scholar
• Schwartz RE, Fleming HE, Khetani SR, Bhatia SN. Pluripotent stem cell-derived hepatocyte-like cells. Biotechnol Adv 2014;32(2):504-13
   PubMed Web of Science ®Google Scholar
• Schwartz RE, Trehan K, Andrus L, et al. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci USA 2012;109:2544-8
   PubMed Web of Science ®Google Scholar
• Rashid ST, Corbineau S, Hannan N, et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 2010;120:3127-36
   PubMed Web of Science ®Google Scholar
• Nagamoto Y, Tashiro K, Takayama K, et al. The promotion of hepatic maturation of human pluripotent stem cells in 3D co-culture using type I collagen and Swiss 3T3 cell sheets. Biomaterials 2012;33:4526-34
   PubMed Web of Science ®Google Scholar
• Yu Y, Liu H, Ikeda Y, et al. Hepatocyte-like cells differentiated from human induced pluripotent stem cells: relevance to cellular therapies. Stem Cell Res 2012;9:196-207
   PubMed Web of Science ®Google Scholar
• Takebe T, Sekine K, Enomura M, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 2013;499:481-4
   PubMed Web of Science ®Google Scholar
• Hannan NR, Segeritz CP, Touboul T, Vallier L. Production of hepatocyte-like cells from human pluripotent stem cells. Nat Protoc 2013;8:430-7
   PubMed Web of Science ®Google Scholar
• Takayama K, Inamura M, Kawabata K, et al. Efficient generation of functional hepatocytes from human embryonic stem cells and induced pluripotent stem cells by HNF4alpha transduction. Mol Ther 2012;20:127-37
   PubMed Web of Science ®Google Scholar
• Zhu S, Rezvani M, Harbell J, et al. Mouse liver repopulation with hepatocytes generated from human fibroblasts. Nature 2014;508(7494):93-7
   PubMed Web of Science ®Google Scholar
• Huang P, Zhang L, Gao Y, et al. Direct reprogramming of human fibroblasts to functional and expandable hepatocytes. Cell Stem Cell 2014;14:370-84
   PubMed Web of Science ®Google Scholar
• Du Y, Wang J, Jia J, et al. Human hepatocytes with drug metabolic function induced from fibroblasts by lineage reprogramming. Cell Stem Cell 2014;14:394-403
   PubMed Web of Science ®Google Scholar
• Roelandt P, Obeid S, Paeshuyse J, et al. Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus. J Hepatol 2012;57:246-51
   PubMed Web of Science ®Google Scholar
• Takayama K, Inamura M, Kawabata K, et al. Generation of metabolically functioning hepatocytes from human pluripotent stem cells by FOXA2 and HNF1alpha transduction. J Hepatol 2012;57:628-36
   PubMed Web of Science ®Google Scholar
• Song Z, Cai J, Liu Y, et al. Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Res 2009;19:1233-42
   PubMed Web of Science ®Google Scholar
• Yagi H, Parekkadan B, Suganuma K, et al. Long-term superior performance of a stem cell/hepatocyte device for the treatment of acute liver failure. Tissue Eng Part A 2009;15:3377-88
   Google Scholar
• Saito M, Matsuura T, Masaki T, et al. Reconstruction of liver organoid using a bioreactor. World J Gastroenterol 2006;12:1881-8
   PubMed Web of Science ®Google Scholar
• Dos Santos F, Campbell A, Fernandes-Platzgummer A, et al. A xenogeneic-free bioreactor system for the clinical-scale expansion of human mesenchymal stem/stromal cells. Biotechnol Bioeng 2014;111:1116-27
   PubMed Web of Science ®Google Scholar
• Cosgrove BD, King BM, Hasan MA, et al. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol 2009;237:317-30
   PubMed Web of Science ®Google Scholar
• Parekkadan B, van Poll D, Suganuma K, et al. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS ONE 2007;2:e941
   PubMed Web of Science ®Google Scholar
• Sgroi A, Gonelle-Gispert C, Morel P, et al. Interleukin-1 receptor antagonist modulates the early phase of liver regeneration after partial hepatectomy in mice. PLoS ONE 2011;6:e25442
   PubMedGoogle Scholar
• Shinoda M, Tilles AW, Wakabayashi G, et al. Treatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepatocytes producing interleukin-1 receptor antagonist. Tissue Eng 2006;12:1313-23
   PubMedGoogle Scholar
• Taniguchi T. Cytokine adsorbing columns. Contrib Nephrol 2010;166:134-41
   PubMed Web of Science ®Google Scholar
• Bernal W, Hall C, Karvellas CJ, et al. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology 2007;46:1844-52
   PubMed Web of Science ®Google Scholar
• Knudsen GM, Paulson OB, Hertz MM. Kinetic analysis of the human blood-brain barrier transport of lactate and its influence by hypercapnia. J Cereb Blood Flow Metab 1991;11:581-6
   PubMed Web of Science ®Google Scholar
• Bosoi CR, Zwingmann C, Marin H, et al. Increased brain lactate is central to the development of brain edema in rats with chronic liver disease. J Hepatol 2013;60(3):554-60
   PubMed Web of Science ®Google Scholar
• Tofteng F, Jorgensen L, Hansen BA, et al. Cerebral microdialysis in patients with fulminant hepatic failure. Hepatology 2002;36:1333-40
   PubMed Web of Science ®Google Scholar
• Chen T, Qian YZ, Rice A, et al. Brain lactate uptake increases at the site of impact after traumatic brain injury. Brain Res 2000;861:281-7
   PubMed Web of Science ®Google Scholar
• Smith D, Pernet A, Hallett WA, et al. Lactate: a preferred fuel for human brain metabolism in vivo. J Cereb Blood Flow Metab 2003;23:658-64
   PubMed Web of Science ®Google Scholar
• Oria M, Jalan R. Brain lactate in hepatic encephalopathy: Friend or foe? J Hepatol 2014;60(3):476-7
   PubMed Web of Science ®Google Scholar
• Wratten ML, Sereni L, Tetta C. Oxidation of albumin is enhanced in the presence of uremic toxins. Ren Fail 2001;23:563-71
   PubMed Web of Science ®Google Scholar
• Kouoh F, Gressier B, Luyckx M, et al. Antioxidant properties of albumin: effect on oxidative metabolism of human neutrophil granulocytes. Farmaco 1999;54:695-9
   PubMedGoogle Scholar
• Arroyo V, Garcia-Martinez R, Salvatella X. Human serum albumin, systemic inflammation and cirrhosis. J Hepatol 2014;61(2):396-407
   PubMed Web of Science ®Google Scholar
• Wilhelm AJ, Zabalawi M, Owen JS, et al. Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/- mice. J Biol Chem 2010;285:36158-69
   PubMed Web of Science ®Google Scholar
• Etogo-Asse FE, Vincent RP, Hughes SA, et al. High density lipoprotein in patients with liver failure; relation to sepsis, adrenal function and outcome of illness. Liver Int 2012;32:128-36
   PubMed Web of Science ®Google Scholar
• Wang N, Tsuruoka S, Yamamoto H, et al. The bioreactor with CYP3A4- and glutamine synthetase-introduced HepG2 cells: treatment of hepatic failure dog with diazepam overdosage. Artif Organs 2005;29:681-4
   PubMed Web of Science ®Google Scholar
• Ahboucha S, Butterworth RF. Role of endogenous benzodiazepine ligands and their GABA-A--associated receptors in hepatic encephalopathy. Metab Brain Dis 2005;20:425-37
   PubMed Web of Science ®Google Scholar
• Enosawa S, Miyashita T, Saito T, et al. The significant improvement of survival times and pathological parameters by bioartificial liver with recombinant HepG2 in porcine liver failure model. Cell Transplant 2006;15:873-80
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Cytochrome p450 and chemical toxicology. Chem Res Toxicol 2008;21:70-83
   PubMed Web of Science ®Google Scholar
• Oe S, Lemmer ER, Conner EA, et al. Intact signaling by transforming growth factor beta is not required for termination of liver regeneration in mice. Hepatology 2004;40:1098-105
   PubMed Web of Science ®Google Scholar
• Suh KS, Lilja H, Kamohara Y, et al. Bioartificial liver treatment in rats with fulminant hepatic failure: effect on DNA-binding activity of liver-enriched and growth-associated transcription factors. J Surg Res 1999;85:243-50
   PubMed Web of Science ®Google Scholar
• Zeilinger K, Schreiter T, Darnell M, et al. Scaling down of a clinical three-dimensional perfusion multicompartment hollow fiber liver bioreactor developed for extracorporeal liver support to an analytical scale device useful for hepatic pharmacological in vitro studies. Tissue Eng Part C Methods 2011;17:549-56
   PubMed Web of Science ®Google Scholar
• Darnell M, Ulvestad M, Ellis E, et al. In vitro evaluation of major in vivo drug metabolic pathways using primary human hepatocytes and HepaRG cells in suspension and a dynamic three-dimensional bioreactor system. J Pharmacol Exp Ther 2012;343:134-44
   PubMed Web of Science ®Google Scholar
• Si-Tayeb K, Noto FK, Nagaoka M, et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 2010;51:297-305
   PubMed Web of Science ®Google Scholar
• Chen YF, Tseng CY, Wang HW, et al. Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol. Hepatology 2012;55:1193-203
   PubMed Web of Science ®Google Scholar